Can Oruka Therapeutics, Inc. cover its short-term obligations?

Its current ratio is 23.76 — current assets exceed current liabilities.

Where does Oruka Therapeutics, Inc.'s balance sheet data come from?

Every line is extracted from Oruka Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Oruka Therapeutics, Inc. ORKA Balance Sheet Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY QoQ

Simplified Detailed

	TTM Q1 '26	TTM Q4 '25	TTM Q3 '25	TTM Q2 '25	TTM Q1 '25
Cash and cash equivalents	$49.52M-40.7%	$46.94M-23.8%	$91.25M+134%	$65.4M+332%	$83.57M+201%
Short-term investments	$107.12M—	$142.54M—	$151.76M—	——	——
Prepaid expenses and other current assets	$6.42M+115%	$6.81M+458%	$6.01M+190%	$3.61M+572%	$2.99M+290%
Total current assets	$395.25M+12.3%	$343.86M-8.8%	$355.16M-14.0%	$332.01M+882%	$352.08M+35,208,200%
Property and equipment, net	$318K+100%	$288K+77.8%	$253K+58.1%	$174K+4,250%	$159K+2,171%
Operating lease right-of-use assets	$1.69M+107%	$1.83M+1,019,498,507%	$1.97M+110%	$2.08M+25,850%	$814K+4,688%
Intangible assets, net	——	——	——	——	——
Deferred tax assets	——	——	——	——	——
Other non-current assets	$103K0.0%	$103K+140%	$103K+140%	$103K+758%	$103K+758%
Total investment securities	$446.43M—	$432.65M—	$409.67M—	——	——
Total assets	$504.48M+33.8%	$488.62M+23.4%	$509.25M+23.0%	$357.42M+956%	$377.11M+37,711,100%
Accrued expenses	$9.29M+64.0%	$10.59M+2,398%	$8.65M+406%	$3.58M+3,183%	$5.66M+6,642%
Accrued compensation	$1.71M—	$5.27M—	$2.85M—	$1.68M—	——
Operating lease liabilities, current	$680K+140%	$619K+191%	$419K+187%	$660K+2,650%	$283K+490%
Total current liabilities	$16.63M+41.9%	$15.37M+17.9%	$20.97M+16.2%	$12.11M+853%	$11.72M+641%
Deferred tax liabilities	——	——	——	——	——
Operating lease liabilities, non-current	$1.13M+69.7%	$1.31M+73.9%	$1.49M+77.3%	$1.67M—	$664K—
Operating Lease Liabilities (Total)	$1.81M+90.8%	$1.93M+99.6%	$1.91M+93.5%	$2.33M+9,592%	$947K+1,873%
Total liabilities	$17.76M+43.4%	$16.69M+20.9%	$22.46M+19.0%	$13.78M+984%	$12.39M+683%
Common stock	545M0.0%	545M0.0%	545M0.0%	545M+3,892,757%	545M+738%
Additional paid-in capital	$705.2M+51.2%	$657.56M+42.0%	$643.2M+61.9%	$470M+108%	$466.49M+46,648,500%
Retained earnings	-$220.98M-111%	-$189.16M-126%	-$159.57M-175%	-$129.3M+33.2%	-$104.72M+45.1%
Accumulated other comprehensive income (loss)	-$480K—	$546K—	$185K—	——	——
Total stockholders' equity	$486.72M+33.4%	$471.93M+23.5%	$486.79M+42.2%	$343.64M+1,286%	$364.73M+36,472,400%
Total liabilities and stockholders' equity	$504.48M+33.8%	$488.62M+23.4%	$509.25M+23.0%	$357.42M+956%	$377.11M+37,711,100%
Available-for-Sale Debt Securities - Amortized Cost	$492.33M—	$476.85M—	$498.48M—	——	——
AFS and Trading Securities - Unrealized Loss Position (<12 Months) Fair Value	$348.72M—	$29.4M—	$183.28M—	——	——
Available-for-Sale Debt Securities - Unrealized Loss Position (<12 Months)	$348.72M—	$29.4M—	$183.28M—	——	——
Available-for-Sale Debt Securities - Unrealized Loss Position	$553K—	$10K—	$80K—	——	——
AFS and Trading Securities - Unrealized Loss Position Fair Value	$348.72M—	$29.4M—	$183.28M—	——	——
AFS and Trading Securities - Unrealized Loss Position (<12 Months) Fair Value	$348.72M—	$29.4M—	$183.28M—	——	——
Cash, Cash Equivalents, and Marketable Securities	$348.72M—	$29.4M—	$183.28M—	——	——
Short- term Investments	$339.31M—	$290.11M—	$257.9M—	——	——
Deferred Tax Assets and Other Non-Current Assets	$103K0.0%	$103K+140%	$103K+140%	$103K+758%	$103K+758%
Indefinite-Lived Research and Development Assets	——	——	——	——	——
Investments - Amortized Cost Basis	$492.33M—	$476.85M—	$498.48M—	——	——
Net Investment in Lease	$1.69M+107%	$1.83M+109%	$1.97M+110%	$2.08M+25,850%	$814K+4,688%
Investments and Cash	$496M—	$479.6M—	$500.9M—	——	——
Long- term Investments	$107.12M—	$142.54M—	$151.76M—	——	——
Operating lease right-of-use assets	$1.69M+107%	$1.83M+109%	$1.97M+110%	$2.08M+25,850%	$814K+4,688%
Other non-current assets	$103K0.0%	$103K+140%	$103K+140%	$103K+758%	$103K+758%
Operating Lease Right-of-Use Assets in Other Assets	$1.69M+107%	$1.83M+109%	$1.97M+110%	$2.08M+25,850%	$814K+4,688%
Software and Technology Licenses, Net	$103K0.0%	$103K+140%	$103K+140%	$103K+758%	$103K+758%
Tax Credit Carryforward Valuation Allowance	——	——	——	——	——
Current Liabilities Assumed in Business Combination	——	——	——	——	——
Lease Liability Payments - 2020 (Remaining Three Months)	——	——	——	——	——
Operating Lease Liability Payments - 2024 (Lessee)	$397K—	$768K—	$768K—	$768K—	——
Operating Lease Liability Payments - 2025 (Lessee)	$397K—	$304K—	$304K—	$304K—	——
Lease Liability Payments - Due Year Two	$397K—	$768K—	$768K—	$768K—	——
Lease Liability Payments - Due Year Three	$304K—	——	——	——	——
Lease Liability Payments - Remainder of Fiscal Year	$768K—	$822K—	$822K—	$822K—	——
Operating Lease Liability Payments Due	$2.11M—	$2.29M—	$2.33M—	$2.82M—	——
Operating Lease Liability - Undiscounted Excess Amount	$299K—	$359K—	$421K—	$492K—	——
Professional Service Fees Payable	$775K—	$941K—	$1.02M—	$138K—	——
Operating Lease Liability Payments - 2026 (Lessee)	$304K—	$397K—	$397K—	$397K—	——
Operating Lease Liability Payments - 2027 (Lessee)	$304K—	——	——	——	——
Accrued expenses and other liabilities	$9.29M—	$10.59M—	$8.65M—	$3.58M—	——
Total debt	$1.81M+90.8%	$1.93M+99.6%	$1.91M+93.5%	$2.33M+9,592%	$947K+1,873%
Unrecognized Tax Benefits	——	——	——	——	——
Common Stock Par Value Per Share	$0.00—	$0.00—	$0.00—	$0.00—	——
Common Stock Shares Issued	50.2M—	48.7M—	48.4M—	37.5M—	——
Common Stock Shares Outstanding	$160.99M—	$69.97M—	$30.94M—	$6.63M—	——
Common stock; $0.001 par value; 6,000 shares authorized; 3,755 and 3,751 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively	$50K+35.1%	$49K+32.4%	$48K+37.1%	$37K+164%	$37K+164%
Investments - Gross Unrealized Losses	$348.72M—	$29.4M—	$183.28M—	——	——
Number of Exercisable Options	$160.99M—	$69.97M—	$30.94M—	$6.63M—	——
Number of Vested and Expected to Vest Options	5.3M—	4M—	3.8M—	3.7M—	——
Share-Based Payment Award Options Outstanding - Number	5.3M—	4M—	3.8M—	3.7M—	——
Share-Based Payment - Unrecognized Cost of Nonvested Awards	——	——	——	——	——
Shares Reserved for Future Issuance Under Stock Plans	34.9M—	31.9M—	31.9M—	——	——
Unrealized Gains on Investments	$73K—	$556K—	$265K—	——	——
Unrealized Losses on Investments (Before Tax)	$553K—	$10K—	$80K—	——	——
Weighted Average Exercise Price of Outstanding Options	$18.66—	$12.61—	$11.90—	$11.72—	——
Weighted Average Exercise Price of Vested and Expected to Vest Options	$18.66—	$12.61—	$11.90—	$11.72—	——
Cumulative Cost Basis	$492.33M—	$476.85M—	$498.48M—	——	——
Professional service fees	$775K—	$941K—	$1.02M—	$138K—	——
Accrued Research And Development	$6.81M—	$4.38M—	$4.79M—	$1.76M—	——
Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax	$553K—	$10K—	$80K—	——	——
Gross Unrealized Gains	$73K—	$556K—	$265K—	——	——
Total	$492.33M—	$476.85M—	$498.48M—	——	——
Available for sale investments	$491.85M—	$477.4M—	$498.66M—	——	——
Cash, cash equivalents and short-term investments	——	——	——	——	——
Common stock, capital shares reserved for future issuance	$34.85M—	$31.9M—	$31.92M—	——	——
Common stock, par value (in dollars per share)	$0—	$0—	$0—	$0—	——
Common stock, shares authorized (in shares)	$545M—	$545M—	$545M—	$545M—	——
Common stock, shares issued (in shares)	$50.17M—	$48.72M—	$48.38M—	$37.45M—	——
Common Stock, Shares, Outstanding	$50.17M—	$48.72M—	$48.38M—	$37.45M—	——
Less than 12 months	$348.72M—	$29.4M—	$183.28M—	——	——
Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss	$553K—	$10K—	$80K—	——	——
Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss	$553K—	$10K—	$80K—	——	——
Debt Securities, Available-for-Sale, Unrealized Loss Position	$348.72M—	$29.4M—	$183.28M—	——	——
Deferred Tax Liabilities, Gross	——	——	——	——	——
Deferred Tax Assets, Goodwill and Intangible Assets	——	——	——	——	——
Deferred Tax Assets, Gross	——	——	——	——	——
Deferred Tax Assets Lease Liabilities	——	——	——	——	——
Deferred Tax Assets, Operating Loss Carryforwards	——	——	——	——	——
R&D credit carryforward	——	——	——	——	——
Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost	——	——	——	——	——
Allowance for unfunded lending related commitments	——	——	——	——	——
Deferred Tax Assets, Valuation Allowance	——	——	——	——	——
Deferred Tax Liabilities Right Of Use Asset	——	——	——	——	——
Unrecognized compensation cost related to non-vested awards	——	——	——	——	——
Lessee Operating Lease Liability Payments Due	$2.11M—	$2.29M—	$2.33M—	$2.82M—	——
Lessee Operating Lease Liability Undiscounted Excess Amount	$299K—	$359K—	$421K—	$492K—	——
Marketable Securities	$446.43M—	$432.65M—	$409.67M—	——	——
Operating Lease Weighted Average Discount Rate Percent	——	——	——	——	——
Operating Loss Carryforwards As A Percentage Of Taxable Income	——	——	——	——	——
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price	$18.66—	$12.61—	$11.9—	$11.72—	——
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number	$1.27M—	$972.9K—	——	——	——
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number	$5.3M—	$3.95M—	$3.81M—	$3.67M—	——
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number	$5.3M—	$3.95M—	$3.81M—	$3.67M—	——
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price	$18.66—	$12.61—	$11.9—	$11.72—	——
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value	$160.99M—	$69.97M—	$30.94M—	$6.63M—	——
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value	$160.99M—	$69.97M—	$30.94M—	$6.63M—	——
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price	$12.11—	$10.75—	——	——	——
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value	$46.91M—	$19.03M—	——	——	——
Unrecognized tax benefits	——	——	——	——	——
Remainder of Fiscal Year 2024	——	——	——	——	——

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Can Oruka Therapeutics, Inc. cover its short-term obligations?: Its current ratio is 23.76 — current assets exceed current liabilities.
Where does Oruka Therapeutics, Inc.'s balance sheet data come from?: Every line is extracted from Oruka Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.